Quantum Leap Energy LLC Announces Private Placement of Convertible Notes Led by American Ventures LLC
Rhea-AI Summary
ASP Isotopes (NASDAQ: ASPI) subsidiary Quantum Leap Energy LLC commenced a private placement of convertible notes with an initial closing of $64.3 million.
The unsecured Notes may convert into QLE common equity prior to maturity at the lower of 80% of the applicable per-share price or a per-share value based on a set valuation cap; maturity is five years from initial closing. QLE cannot repay the Notes before maturity absent a change of control.
Proceeds are intended to build and develop laser enrichment production facilities and for general corporate purposes. The offering was led by ASPI and American Ventures LLC with capital contributions from Eric Trump and Donald Trump Jr.; initial closing is expected on or about November 10, 2025. Canaccord Genuity and Ocean Wall acted as placement agents.
Positive
- $64.3M initial convertible note closing
- Proceeds designated to build laser enrichment production facilities
- Convertible structure offers equity conversion at a discounted conversion price (80%) or valuation cap
Negative
- Notes are unsecured, raising creditor-recovery risk
- Potential shareholder dilution if Notes convert into equity
- QLE may not repay Notes prior to maturity unless a change of control occurs
- Automatic conversion of 2024 Convertible Notes yields no cash proceeds to QLE or ASP Isotopes
News Market Reaction 87 Alerts
On the day this news was published, ASPI gained 17.49%, reflecting a significant positive market reaction. Argus tracked a peak move of +28.0% during that session. Our momentum scanner triggered 87 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $154M to the company's valuation, bringing the market cap to $1.04B at that time.
Data tracked by StockTitan Argus on the day of publication.
WASHINGTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Quantum Leap Energy LLC (“QLE”), a wholly-owned subsidiary of ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or “ASPI” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced that QLE has commenced an offering of QLE’s convertible notes in a private placement to accredited investors and certain non-U.S. persons. QLE has entered into a definitive convertible note purchase agreement with certain investors for an initial closing of US
The issuance of Notes pursuant to the offering will result in the automatic conversion of QLE’s outstanding convertible promissory notes originally issued in March 2024 and June 2024 (together, the “2024 Convertible Notes”), pursuant to their terms.
The Notes will be unsecured and may be convertible into common equity securities of QLE, prior to maturity, and upon the occurrence of certain events, including an initial public offering, direct listing or a future equity financing, in each case at a price per share equal to the lower of
The Notes will mature on the fifth anniversary of the initial closing, unless converted in accordance with their terms prior to such date. QLE may not repay the Notes prior to maturity, unless a change of control transaction occurs.
QLE intends to use the net proceeds from the offering to build and develop laser enrichment production facilities, as well as for general corporate purposes. Neither QLE nor the Company will receive any proceeds from the automatic conversion of the 2024 Convertible Notes into Notes.
The offering was led by ASPI and American Ventures LLC, with capital contributions from both Eric Trump and Donald Trump Jr. The initial closing of the offering is expected to be on or about November 10, 2025, subject to satisfaction of customary closing conditions.
The Notes are being offered to institutional investors that qualify as “accredited investors” (within the meaning of Rule 501(a) of the United States Securities Act of 1933, as amended (the "Securities Act")) or investors that are not a person in the United States or a U.S. Person (within the meaning of Rule 902(k) of Regulation S promulgated under the Securities Act). The Notes and the common equity securities of QLE deliverable upon conversion of the Notes (if any) have not been and will not be registered under the Securities Act or any other applicable securities laws, and may not be sold or otherwise transferred in the United States except under an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any other applicable securities laws.
QLE may issue additional Notes in subsequent closings to investors who are non-U.S. persons in transactions outside of the United States in reliance on Regulation S under the Securities Act.
Canaccord Genuity acted as placement agent in the United States and Ocean Wall Limited acted as placement agent outside the United States.
This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any securities, nor shall there be a sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).
There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. We believe the ASP technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as “believes,” “plans,” “anticipates,” “expects,” “estimates,” “projects,” “will,” “may,” “might,” and words of a similar nature. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including, but not limited to: risks and uncertainties related to the Company’s proposed offering of convertible notes of Quantum Leap Energy LLC, or factors that result in changes to the Company’s anticipated results of operations related to its products and technologies. These and other risks and uncertainties are described more fully in Part I, Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and any amendments thereto, and in the Company’s subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.
Contacts
Jason Assad – Investor relations
Email: JAssad@ASPIsotopes.com
FAQ
How much is QLE raising in the initial convertible note closing for ASPI (ASPI)?
What are the conversion terms of QLE's Notes in the ASPI (ASPI) offering?
When do QLE's convertible notes issued in the ASPI (ASPI) deal mature and can they be repaid early?
What will ASPI/QLE use the proceeds from the $64.3M convertible note offering for?
Who led the private placement of QLE convertible notes associated with ASPI (ASPI)?
Will ASP Isotopes receive cash from conversion of prior 2024 notes in the ASPI (ASPI) transaction?
